The Chemical Genomics Centre

The Chemical Genomics Centre is an initiative of the Max Planck Society in cooperation with Merck Serono, AstraZeneca, Boehringer Ingelheim, Bayer HealthCare and Bayer CropScience. It stands for high quality research in the area of Chemical Genomics and strong collaborations between industry and Max Planck research.

Based on the experience gained in the first funding period of the CGC (2005-2010) the concept of the second funding period of the CGC (2012-2017) was developed further and evolved to guarantee efficient research and collaboration among the participating groups. The scientific focus will remain to be on the chemical-biological analysis of biological phenomena through the use of small molecules.

greber

 grossmann

Hennig Start  ottmann
Dr. Boris Greber
Controlling stem cell fate decisions
Dr. Tom N. Grossmann
Chemical control of protein localization
Dr. Sven Hennig
Therapeutic Transcriptome Modifications
Dr. Christian Ottmann
Stabilizers of 14-3-3 protein-protein interactions

News

Merck KGaA and Lead Discovery Center Enter Collaboration for the Discovery of Anti-Cancer Compounds
european pharmaceutical
review - Internetseite
20. Januar 2011

Lead Discovery Center and Merck to collaborate on anti-cancer compounds discovery
Science Business - Internetseite
22. Januar 2011

Unkraut vergeht doch
Ruhr Nachrichten
25. November 2009

Publications

List of Publications: Dr. B. Greber

List of Publications: Dr. T. N. Grossmann

List of Publications: Dr. S. Hennig

List of Publications: Dr. C. Ottmann

unten